PHS
JAZZ icon

PFM Health Sciences’s Jazz Pharmaceuticals JAZZ Stock Holding History

PFM Health Sciences’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-128,500
Closed -$20.5M – 90
2022
Q4 		$20.5M Buy
+128,500
New +$18.8M 0.73% 52

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

PFM Health Sciences's JAZZ Position: Q2 2026 in Review

PFM Health Sciences reduced its Jazz Pharmaceuticals (JAZZ) stake by 9.8% in Q2 2026, selling an estimated $3.81M and leaving 160,768 shares worth $38.7M. The position accounts for 3.32% of the portfolio, ranked #4.

PFM Health Sciences first reported a position in JAZZ in Q1 2015 and has held it in 19 quarters since. The position peaked at $213M in Q2 2018. 645 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • PFM Health Sciences held 160,768 shares of Jazz Pharmaceuticals worth $38.7M as of Q2 2026.
  • PFM Health Sciences sold 17,376 Jazz Pharmaceuticals shares in Q2 2026, an estimated $3.81M.
  • Jazz Pharmaceuticals made up 3.32% of PFM Health Sciences's portfolio in Q2 2026, its #4 holding.
  • PFM Health Sciences first reported a position in Jazz Pharmaceuticals in Q1 2015 and has held it in 19 quarters since.
  • PFM Health Sciences's Jazz Pharmaceuticals position peaked at $213M in Q2 2018.
  • 645 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.